董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas J. Errico | 男 | Founder and Director | 73 | 16.99万美元 | 未持股 | 2025-09-02 |
| Daniel S. Goldberger | 男 | Chief Executive Officer and Director | 66 | 161.86万美元 | 未持股 | 2025-09-02 |
| Julie A. Goldstein | 女 | Director | 67 | 16.26万美元 | 未持股 | 2025-09-02 |
| Patricia Wilber | 女 | Director | 63 | 16.75万美元 | 未持股 | 2025-09-02 |
| Elena Bonfiglioli | 女 | Director | 53 | 未披露 | 未持股 | 2025-09-02 |
| Thomas M. Patton | 男 | Director | 61 | 17.27万美元 | 未持股 | 2025-09-02 |
| John P. Gandolfo | 男 | Director | 64 | 17.74万美元 | 未持股 | 2025-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas J. Errico | 男 | Founder and Director | 73 | 16.99万美元 | 未持股 | 2025-09-02 |
| Daniel S. Goldberger | 男 | Chief Executive Officer and Director | 66 | 161.86万美元 | 未持股 | 2025-09-02 |
| Joshua S. Lev | 男 | Chief Financial Officer | 40 | 70.38万美元 | 未持股 | 2025-09-02 |
董事简历
中英对照 | 中文 | 英文- Thomas J. Errico
-
ThomasJ.Errico自2005年9月以来一直担任我们的董事会成员，当时他与JosephP.Errico和PeterS.Staats共同创立了该公司。Errico博士从1986年开始一直担任董事会认证的整形外科医生，目前担任NYU Langone Health整形外科脊柱外科的部门主管，他从1997年开始担任该职位。他目前也是纽约大学医学院（NYU School of Medicine）骨科和神经外科教授。此外，Errico博士是国际脊柱外科进步协会（International Society for Advancement of Spine Surgery）的成员，并从2010年到2011年担任其总裁。他也是北美脊柱学会（North American Spine Society）的原始成员，并从2003年到2004年担任其总裁。Errico博士在梦百合行业创立了多家公司，包括SpineCore，Inc.，2002年，他在该公司担任董事，直到2004年该公司被出售给Stryker，Inc.。Errico博士还于2004年1月成为K2mGroupHoldings，Inc.的创始成员。Errico博士拥有罗格斯大学（Rutgers University）动物学学士学位和罗格斯医学院（Rutgers Medical School，前身为新泽西医学和牙科大学）的医学博士学位。
Thomas J. Errico,has been a board-certified orthopedic surgeon since 1986 and currently serves as a pediatric orthopedic spine surgeon at Nicklaus Children's Hospital. Dr. Errico also currently serves as the Associate Director of Research at Nicklaus Children's Hospital. He also is an associate Professor of Orthopedic Surgery at the University of Miami School of Medicine. He previously served as the chief, Division of Spine Surgery in Orthopedics, at NYU Langone Health from 1997 until 2018. He currently serves on the board of Setting Scoliosis Straight, a nonprofit organization focused on advancing medical techniques in the treatment of spinal deformities and was an adjunct professor of the Department of Orthopedic Surgery at NYU Grossman School of Medicine. In addition, Dr. Errico is a member of the International Society for the Advancement of Spine Surgery and served as its president from 2010 to 2011. He is also an original member of the North American Spine Society and served as its president from 2003 to 2004. Dr. Errico has founded multiple companies in the healthcare industry, including Spinecore, Inc. in 2001, where he served as a director until it was sold to Stryker, Inc. in 2004. Dr. Errico was also a founding member of K2M Group Holdings, Inc. in January 2004. Dr. Errico holds a B.S. in zoology from Rutgers University and an M.D. from Rutgers Medical School, formerly the University of Medicine and Dentistry of New Jersey. - ThomasJ.Errico自2005年9月以来一直担任我们的董事会成员，当时他与JosephP.Errico和PeterS.Staats共同创立了该公司。Errico博士从1986年开始一直担任董事会认证的整形外科医生，目前担任NYU Langone Health整形外科脊柱外科的部门主管，他从1997年开始担任该职位。他目前也是纽约大学医学院（NYU School of Medicine）骨科和神经外科教授。此外，Errico博士是国际脊柱外科进步协会（International Society for Advancement of Spine Surgery）的成员，并从2010年到2011年担任其总裁。他也是北美脊柱学会（North American Spine Society）的原始成员，并从2003年到2004年担任其总裁。Errico博士在梦百合行业创立了多家公司，包括SpineCore，Inc.，2002年，他在该公司担任董事，直到2004年该公司被出售给Stryker，Inc.。Errico博士还于2004年1月成为K2mGroupHoldings，Inc.的创始成员。Errico博士拥有罗格斯大学（Rutgers University）动物学学士学位和罗格斯医学院（Rutgers Medical School，前身为新泽西医学和牙科大学）的医学博士学位。
- Thomas J. Errico,has been a board-certified orthopedic surgeon since 1986 and currently serves as a pediatric orthopedic spine surgeon at Nicklaus Children's Hospital. Dr. Errico also currently serves as the Associate Director of Research at Nicklaus Children's Hospital. He also is an associate Professor of Orthopedic Surgery at the University of Miami School of Medicine. He previously served as the chief, Division of Spine Surgery in Orthopedics, at NYU Langone Health from 1997 until 2018. He currently serves on the board of Setting Scoliosis Straight, a nonprofit organization focused on advancing medical techniques in the treatment of spinal deformities and was an adjunct professor of the Department of Orthopedic Surgery at NYU Grossman School of Medicine. In addition, Dr. Errico is a member of the International Society for the Advancement of Spine Surgery and served as its president from 2010 to 2011. He is also an original member of the North American Spine Society and served as its president from 2003 to 2004. Dr. Errico has founded multiple companies in the healthcare industry, including Spinecore, Inc. in 2001, where he served as a director until it was sold to Stryker, Inc. in 2004. Dr. Errico was also a founding member of K2M Group Holdings, Inc. in January 2004. Dr. Errico holds a B.S. in zoology from Rutgers University and an M.D. from Rutgers Medical School, formerly the University of Medicine and Dentistry of New Jersey.
- Daniel S. Goldberger
-
DanielS.Goldberger自2018年4月以来一直担任Koru的董事。自2019年10月以来，Goldberger先生一直担任Electrocore Inc（一家将迷走神经刺激疗法商业化的上市公司）的首席执行官。从2017年10月至2019年1月，Goldberger先生担任Milestone Medical，Inc.的首席执行官。在此之前，他曾于2013年8月至2017年1月担任Xtant MedicalHoldings，Inc.首席执行官。他还从2007年4月到2013年2月担任Sound Surgical Technologies LLC首席执行官。Goldberger先生曾任职于Xtant MedicalHoldings，Inc.公司、Sound Surgical公司、Xcorporeal公司和Glucon公司的董事会。他目前担任投资基金Meridian Capital和Wellfleet Capital的顾问。Goldberger先生在M.I.T.获得机械工程学士学位，在斯坦福大学（Stanford University）获得机械工程硕士学位，并在斯坦福董事学院（Stanford Directors College）就读。
Daniel S. Goldberger,served as a director of Koru Medical Systems, a manufacturer of infusion pump systems, from April 2017 until May 2022 and he served as its executive chairman from August 2017 until September 2019. From January 2018 to September 2019, Mr. Goldberger served as the chief executive officer of Synergy Disc Replacement Inc., a private company commercializing a proprietary total disc implant for cervical spine therapy. From July 2017 to September 2017, Mr. Goldberger served as chief executive officer of Milestone Medical, Inc. Prior to this he served as the chief executive officer of Xtant Medical Holdings, Inc. from August 2013 to January 2017. He also served on the board and as the chief executive officer of Sound Surgical Technologies LLC from April 2007 to February 2013. Mr. Goldberger has also served on the boards of Xtant Medical Holdings, Inc., Sound Surgical, Xcorporeal. Theragen, Inc., and Glucon. Mr. Goldberger earned a B.S. in mechanical engineering from The Massachusetts Institute of Technology, and a M.S. in mechanical engineering from Stanford University. - DanielS.Goldberger自2018年4月以来一直担任Koru的董事。自2019年10月以来，Goldberger先生一直担任Electrocore Inc（一家将迷走神经刺激疗法商业化的上市公司）的首席执行官。从2017年10月至2019年1月，Goldberger先生担任Milestone Medical，Inc.的首席执行官。在此之前，他曾于2013年8月至2017年1月担任Xtant MedicalHoldings，Inc.首席执行官。他还从2007年4月到2013年2月担任Sound Surgical Technologies LLC首席执行官。Goldberger先生曾任职于Xtant MedicalHoldings，Inc.公司、Sound Surgical公司、Xcorporeal公司和Glucon公司的董事会。他目前担任投资基金Meridian Capital和Wellfleet Capital的顾问。Goldberger先生在M.I.T.获得机械工程学士学位，在斯坦福大学（Stanford University）获得机械工程硕士学位，并在斯坦福董事学院（Stanford Directors College）就读。
- Daniel S. Goldberger,served as a director of Koru Medical Systems, a manufacturer of infusion pump systems, from April 2017 until May 2022 and he served as its executive chairman from August 2017 until September 2019. From January 2018 to September 2019, Mr. Goldberger served as the chief executive officer of Synergy Disc Replacement Inc., a private company commercializing a proprietary total disc implant for cervical spine therapy. From July 2017 to September 2017, Mr. Goldberger served as chief executive officer of Milestone Medical, Inc. Prior to this he served as the chief executive officer of Xtant Medical Holdings, Inc. from August 2013 to January 2017. He also served on the board and as the chief executive officer of Sound Surgical Technologies LLC from April 2007 to February 2013. Mr. Goldberger has also served on the boards of Xtant Medical Holdings, Inc., Sound Surgical, Xcorporeal. Theragen, Inc., and Glucon. Mr. Goldberger earned a B.S. in mechanical engineering from The Massachusetts Institute of Technology, and a M.S. in mechanical engineering from Stanford University.
- Julie A. Goldstein
-
Julie A. Goldstein自2022年3月起担任董事会成员。Goldstein女士在产品、媒体和娱乐营销方面拥有30多年的领导专长，她的职业生涯涵盖广播、电视、音乐和戏剧。Goldstein女士的专长包括运营、销售开发、广告和项目管理。她还领导了许多重要的国家和国际营销活动。2013年至2014年，她担任百老汇音乐剧《初次约会》的制片人。在JIVE唱片公司、RCA唱片公司和Virgin唱片公司，她担任营销和开发副总裁。她还曾在新闻集团/电视指南电视网担任市场营销和销售副总裁一职，并开始了她的无线电营销职业生涯。她在支出和战略营销技巧方面的专业知识促成了RCA的转型。她获得了公告牌杂志年度电台推广总监、贝塔斯曼关键管理奖和维珍唱片年度推广总监。Goldstein女士拥有加州州立大学奇科分校的通信和社会福利学士学位。
Julie A. Goldstein,has more than 30 years of leadership expertise in product, media and entertainment marketing, which spans a career in radio, television, music and theater. Ms. Goldstein's specific expertise includes operations, sales development, advertising, and project management. She has also spearheaded many major national and international marketing campaigns. She was a producer for the Broadway musical First Date from 2013 to 2014. At music labels JIVE Records, RCA Records, and Virgin Records, she served as vice president of marketing and development. She also held the position of vice president of marketing and sales at NewsCorp / TV Guide Television Network and began her career in radio marketing. Her expertise around spending and strategic marketing techniques contributed to RCA's turnaround. She received the Billboard Magazine's Radio Promotion Director of the Year, Bertelsmann Key Management Award, and Virgin Records Promotion Director of the Year. Ms. Goldstein holds a B.A. in communications and social welfare from California State University at Chico. - Julie A. Goldstein自2022年3月起担任董事会成员。Goldstein女士在产品、媒体和娱乐营销方面拥有30多年的领导专长，她的职业生涯涵盖广播、电视、音乐和戏剧。Goldstein女士的专长包括运营、销售开发、广告和项目管理。她还领导了许多重要的国家和国际营销活动。2013年至2014年，她担任百老汇音乐剧《初次约会》的制片人。在JIVE唱片公司、RCA唱片公司和Virgin唱片公司，她担任营销和开发副总裁。她还曾在新闻集团/电视指南电视网担任市场营销和销售副总裁一职，并开始了她的无线电营销职业生涯。她在支出和战略营销技巧方面的专业知识促成了RCA的转型。她获得了公告牌杂志年度电台推广总监、贝塔斯曼关键管理奖和维珍唱片年度推广总监。Goldstein女士拥有加州州立大学奇科分校的通信和社会福利学士学位。
- Julie A. Goldstein,has more than 30 years of leadership expertise in product, media and entertainment marketing, which spans a career in radio, television, music and theater. Ms. Goldstein's specific expertise includes operations, sales development, advertising, and project management. She has also spearheaded many major national and international marketing campaigns. She was a producer for the Broadway musical First Date from 2013 to 2014. At music labels JIVE Records, RCA Records, and Virgin Records, she served as vice president of marketing and development. She also held the position of vice president of marketing and sales at NewsCorp / TV Guide Television Network and began her career in radio marketing. Her expertise around spending and strategic marketing techniques contributed to RCA's turnaround. She received the Billboard Magazine's Radio Promotion Director of the Year, Bertelsmann Key Management Award, and Virgin Records Promotion Director of the Year. Ms. Goldstein holds a B.A. in communications and social welfare from California State University at Chico.
- Patricia Wilber
-
Patricia Wilber自2022年3月起担任董事会成员。Wilber女士一直担任首席营销官、全球业务战略家和董事会成员，负责为品牌提供组织和文化转型。她是新的特许经营模式和品牌合作伙伴关系的先驱。威尔伯上次担任欧洲、中东和非洲地区合作伙伴关系执行副总裁、首席营销官兼董事总经理的职位是在2015年至2018年，这是迪士尼市场部的最高职位，在那里她通过领导迪士尼、皮克斯、星球大战和漫威的营销和传播，推动了沃尔特迪斯尼公司旗下知名品牌的增长。此外，她还建立并领导了欧洲、中东和非洲地区40个国家的综合营销、特许经营和伙伴关系职能，包括对欧洲、中东和非洲地区渠道的重大重组，以通过大幅削减开支来促进增长和盈利。她曾于2015年至2018年担任欧洲迪士尼公司的董事会成员，并于2013年至2018年担任神奇游轮公司的董事会成员，该公司通常被称为迪士尼游轮公司。Wilber女士拥有布朗大学历史学学士学位。
Patricia Wilber,has been a chief marketing officer, global business strategist, and board member who delivers organizational and cultural transformation for branding. She is a pioneer in new franchise models and branded partnerships. Ms. Wilber last served as the executive vice president, chief marketing officer, and managing director of partnerships, EMEA, the highest position in the marketing department at The Walt Disney Company from 2015 to 2018, where she drove growth for Disney's marquee brands by leading marketing and communications for Disney, Pixar, Star Wars, and Marvel. Additionally, she established and led EMEA's 40-country integrated marketing, franchise and partnership functions, including a major reorganization of the EMEA channels to boost growth and profitability by significantly reducing expenses. She also currently serves on the board of Zapp Electric Vehicles Group Limited, and on the board of trustees of Yale New Haven Health System and Yale New Haven Hospital, a medical nonprofit organization. She served on the boards of Euro Disney SCA from 2015 to 2018, Magical Cruise Company, more commonly known as the Disney Cruise Line, from 2013 to 2018, and Vibrant Emotional Health from 2022 to 2023. Ms. Wilber holds a B.A. in history from Brown University. - Patricia Wilber自2022年3月起担任董事会成员。Wilber女士一直担任首席营销官、全球业务战略家和董事会成员，负责为品牌提供组织和文化转型。她是新的特许经营模式和品牌合作伙伴关系的先驱。威尔伯上次担任欧洲、中东和非洲地区合作伙伴关系执行副总裁、首席营销官兼董事总经理的职位是在2015年至2018年，这是迪士尼市场部的最高职位，在那里她通过领导迪士尼、皮克斯、星球大战和漫威的营销和传播，推动了沃尔特迪斯尼公司旗下知名品牌的增长。此外，她还建立并领导了欧洲、中东和非洲地区40个国家的综合营销、特许经营和伙伴关系职能，包括对欧洲、中东和非洲地区渠道的重大重组，以通过大幅削减开支来促进增长和盈利。她曾于2015年至2018年担任欧洲迪士尼公司的董事会成员，并于2013年至2018年担任神奇游轮公司的董事会成员，该公司通常被称为迪士尼游轮公司。Wilber女士拥有布朗大学历史学学士学位。
- Patricia Wilber,has been a chief marketing officer, global business strategist, and board member who delivers organizational and cultural transformation for branding. She is a pioneer in new franchise models and branded partnerships. Ms. Wilber last served as the executive vice president, chief marketing officer, and managing director of partnerships, EMEA, the highest position in the marketing department at The Walt Disney Company from 2015 to 2018, where she drove growth for Disney's marquee brands by leading marketing and communications for Disney, Pixar, Star Wars, and Marvel. Additionally, she established and led EMEA's 40-country integrated marketing, franchise and partnership functions, including a major reorganization of the EMEA channels to boost growth and profitability by significantly reducing expenses. She also currently serves on the board of Zapp Electric Vehicles Group Limited, and on the board of trustees of Yale New Haven Health System and Yale New Haven Hospital, a medical nonprofit organization. She served on the boards of Euro Disney SCA from 2015 to 2018, Magical Cruise Company, more commonly known as the Disney Cruise Line, from 2013 to 2018, and Vibrant Emotional Health from 2022 to 2023. Ms. Wilber holds a B.A. in history from Brown University.
- Elena Bonfiglioli
-
Elena Bonfiglioli，自2022年1月起担任微软公司（“微软”）医疗保健、医药生命科学领域的全球业务负责人。在担任这一职务期间，Bonfiglioli女士负责全球范围内医疗保健提供者、支付者和生命科学组织在人工智能转型方面的上市、商业、管道开发和战略合作伙伴关系。自2017年8月以来，Bonfiglioli女士还担任微软欧洲中东非洲（“EMEA”）地区健康和生命科学区域业务负责人。此前，Bonfiglioli女士曾在微软担任其他职务，包括担任欧洲、中东和非洲地区健康产业高级总监。自2023年以来，Bonfiglioli女士一直是欧洲、中东和非洲药品信息协会（DIA）药品咨询委员会的成员。Bonfiglioli女士还不时担任私营生物制药和医疗技术组织的顾问。Bonfiglioli女士拥有欧洲学院欧洲经济学硕士学位、Moderna大学商业和管理经济学Laurea学位以及蒙彼利埃大学应用经济学执照学位。
Elena Bonfiglioli,has been the Global Biness Leader for Healthcare, Pharma Life Sciences of Microsoft Corporation ("Microsoft") since January 2022. In this role, Ms. Bonfiglioli is responsible for go-to-market, commercial, pipeline development and strategic partnerships in artificial intelligence transformation across health providers, payors and life sciences' organizations globally. Ms. Bonfiglioli has also been the Regional Biness Leader for Health and Life Sciences of Microsoft's Europe Middle East Africa ("EMEA") region since Augt 2017. Previoly, Ms. Bonfiglioli held other positions at Microsoft, including as Senior Director – Health Indtry of the EMEA region. Since 2023, Ms. Bonfiglioli has been a member of the Drug Information Association (DIA) Pharma Advisory Council for EMEA. From time to time, Ms. Bonfiglioli has also served as an advisor to private biopharma and medtech organizations. Ms. Bonfiglioli holds a Master's Degree in European Economics from the College of Europe, a Laurea Degree in Biness and Managerial Economics from the University of Moderna, and a Licentiate Degree in applied economics from the University of Montpellier. - Elena Bonfiglioli，自2022年1月起担任微软公司（“微软”）医疗保健、医药生命科学领域的全球业务负责人。在担任这一职务期间，Bonfiglioli女士负责全球范围内医疗保健提供者、支付者和生命科学组织在人工智能转型方面的上市、商业、管道开发和战略合作伙伴关系。自2017年8月以来，Bonfiglioli女士还担任微软欧洲中东非洲（“EMEA”）地区健康和生命科学区域业务负责人。此前，Bonfiglioli女士曾在微软担任其他职务，包括担任欧洲、中东和非洲地区健康产业高级总监。自2023年以来，Bonfiglioli女士一直是欧洲、中东和非洲药品信息协会（DIA）药品咨询委员会的成员。Bonfiglioli女士还不时担任私营生物制药和医疗技术组织的顾问。Bonfiglioli女士拥有欧洲学院欧洲经济学硕士学位、Moderna大学商业和管理经济学Laurea学位以及蒙彼利埃大学应用经济学执照学位。
- Elena Bonfiglioli,has been the Global Biness Leader for Healthcare, Pharma Life Sciences of Microsoft Corporation ("Microsoft") since January 2022. In this role, Ms. Bonfiglioli is responsible for go-to-market, commercial, pipeline development and strategic partnerships in artificial intelligence transformation across health providers, payors and life sciences' organizations globally. Ms. Bonfiglioli has also been the Regional Biness Leader for Health and Life Sciences of Microsoft's Europe Middle East Africa ("EMEA") region since Augt 2017. Previoly, Ms. Bonfiglioli held other positions at Microsoft, including as Senior Director – Health Indtry of the EMEA region. Since 2023, Ms. Bonfiglioli has been a member of the Drug Information Association (DIA) Pharma Advisory Council for EMEA. From time to time, Ms. Bonfiglioli has also served as an advisor to private biopharma and medtech organizations. Ms. Bonfiglioli holds a Master's Degree in European Economics from the College of Europe, a Laurea Degree in Biness and Managerial Economics from the University of Moderna, and a Licentiate Degree in applied economics from the University of Montpellier.
- Thomas M. Patton
-
Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
Thomas M. Patton,is a seasoned healthcare executive and board member with operational, strategic, financial, legal, compliance and transactional experience, from start-ups to growth companies, both public and private. He currently is an advisor to the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic devices corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards' of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsource design and development company from August 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, from October 2015 to November 2021 and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010-2019. His prior experience includes roles as co-founder, president and chief executive officer of QDx, Inc., a developer of unique micro-fluidic diagnostic technology utilizing digital imaging techniques for hematologic analysis, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics from Holy Cross University and J.D. from Georgetown University Law Center. - Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
- Thomas M. Patton,is a seasoned healthcare executive and board member with operational, strategic, financial, legal, compliance and transactional experience, from start-ups to growth companies, both public and private. He currently is an advisor to the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic devices corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards' of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsource design and development company from August 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, from October 2015 to November 2021 and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010-2019. His prior experience includes roles as co-founder, president and chief executive officer of QDx, Inc., a developer of unique micro-fluidic diagnostic technology utilizing digital imaging techniques for hematologic analysis, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics from Holy Cross University and J.D. from Georgetown University Law Center.
- John P. Gandolfo
-
John P. Gandolfo，自2013年10月起担任董事。他拥有大约33年的经验，担任多家快速增长的私人和上市公司的首席财务官（“CFO”），主要关注生命科学、医疗保健和医疗设备领域。在他的职业生涯中，他直接负责融资，包括五次公开发行、财务管理、并购交易和SEC报告。从2018年1月至今，他担任Eyenovia， Inc. （EYEN）的首席财务官，EYEN是一家后期眼科生物制药公司。在此之前，他从2010年7月到2017年9月担任生物制剂公司Xtant Medical Holdings， Inc.的首席财务官。在此之前，从2009年1月到2010年6月，他担任Progenitor Cell Therapy LLC的首席财务官。在此之前，从2007年1月到2009年1月，他担任Power Medical Interventions， Inc.的首席财务官。在此之前，他是Bioject Medical Technologies， Inc.的首席财务官。2000年至2001年9月，他担任Capital Access Network， Inc.的首席财务官；1999年至2000年，他担任Xceed， Inc.的首席财务官。从1994年到1999年，他担任Impath， Inc.的首席财务官和首席运营官。从1987年到1994年，他担任Medical Resources， Inc.的首席财务官。Gandolfo先生此前于2019年至2023年担任Odyssey Health， Inc.（奥德赛集团国际公司）的董事会成员，并担任审计委员会主席。Gandolfo先生目前是Electrocore， Inc. （ECOR）的董事会成员，薪酬委员会主席和审计委员会成员。他持有Rutgers大学的工商管理学士学位。
John P. Gandolfo,has served as Director since October, 2023. Mr. Gandolfo has approximately 33 years of experience as a Chief Financial Officer ("CFO") of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Mr. Gandolfo served as CFO of Eyenovia, Inc., (EYEN) a late-stage ophthalmic biopharmaceutical company, from January 2018 to present. Prior to this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a biologics company, from July 2010 through September 2017. Prior to this, he served as the CFO for Progenitor Cell Therapy LLC from January 2009 to June 2010 and, before that, as CFO of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo was the CFO of Bioject Medical Technologies, Inc. prior to this. He was also the CFO of Capital Access Network, Inc., from 2000 through September 2001, and Xceed, Inc. from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was CFO and COO of Impath, Inc. From 1987 through 1994, he was CFO of Medical Resources, Inc. Mr. Gandolfo previously served on the Board of Directors and was chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., (ODDY) from 2019 until 2023. Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, Inc. (ECOR) and is chair of the Compensation Committee and sits on their audit committee. Mr. Gandolfo received his B.A. degree in Business Administration from Rutgers University. - John P. Gandolfo，自2013年10月起担任董事。他拥有大约33年的经验，担任多家快速增长的私人和上市公司的首席财务官（“CFO”），主要关注生命科学、医疗保健和医疗设备领域。在他的职业生涯中，他直接负责融资，包括五次公开发行、财务管理、并购交易和SEC报告。从2018年1月至今，他担任Eyenovia， Inc. （EYEN）的首席财务官，EYEN是一家后期眼科生物制药公司。在此之前，他从2010年7月到2017年9月担任生物制剂公司Xtant Medical Holdings， Inc.的首席财务官。在此之前，从2009年1月到2010年6月，他担任Progenitor Cell Therapy LLC的首席财务官。在此之前，从2007年1月到2009年1月，他担任Power Medical Interventions， Inc.的首席财务官。在此之前，他是Bioject Medical Technologies， Inc.的首席财务官。2000年至2001年9月，他担任Capital Access Network， Inc.的首席财务官；1999年至2000年，他担任Xceed， Inc.的首席财务官。从1994年到1999年，他担任Impath， Inc.的首席财务官和首席运营官。从1987年到1994年，他担任Medical Resources， Inc.的首席财务官。Gandolfo先生此前于2019年至2023年担任Odyssey Health， Inc.（奥德赛集团国际公司）的董事会成员，并担任审计委员会主席。Gandolfo先生目前是Electrocore， Inc. （ECOR）的董事会成员，薪酬委员会主席和审计委员会成员。他持有Rutgers大学的工商管理学士学位。
- John P. Gandolfo,has served as Director since October, 2023. Mr. Gandolfo has approximately 33 years of experience as a Chief Financial Officer ("CFO") of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Mr. Gandolfo served as CFO of Eyenovia, Inc., (EYEN) a late-stage ophthalmic biopharmaceutical company, from January 2018 to present. Prior to this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a biologics company, from July 2010 through September 2017. Prior to this, he served as the CFO for Progenitor Cell Therapy LLC from January 2009 to June 2010 and, before that, as CFO of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo was the CFO of Bioject Medical Technologies, Inc. prior to this. He was also the CFO of Capital Access Network, Inc., from 2000 through September 2001, and Xceed, Inc. from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was CFO and COO of Impath, Inc. From 1987 through 1994, he was CFO of Medical Resources, Inc. Mr. Gandolfo previously served on the Board of Directors and was chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., (ODDY) from 2019 until 2023. Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, Inc. (ECOR) and is chair of the Compensation Committee and sits on their audit committee. Mr. Gandolfo received his B.A. degree in Business Administration from Rutgers University.
高管简历
中英对照 | 中文 | 英文- Thomas J. Errico
ThomasJ.Errico自2005年9月以来一直担任我们的董事会成员，当时他与JosephP.Errico和PeterS.Staats共同创立了该公司。Errico博士从1986年开始一直担任董事会认证的整形外科医生，目前担任NYU Langone Health整形外科脊柱外科的部门主管，他从1997年开始担任该职位。他目前也是纽约大学医学院（NYU School of Medicine）骨科和神经外科教授。此外，Errico博士是国际脊柱外科进步协会（International Society for Advancement of Spine Surgery）的成员，并从2010年到2011年担任其总裁。他也是北美脊柱学会（North American Spine Society）的原始成员，并从2003年到2004年担任其总裁。Errico博士在梦百合行业创立了多家公司，包括SpineCore，Inc.，2002年，他在该公司担任董事，直到2004年该公司被出售给Stryker，Inc.。Errico博士还于2004年1月成为K2mGroupHoldings，Inc.的创始成员。Errico博士拥有罗格斯大学（Rutgers University）动物学学士学位和罗格斯医学院（Rutgers Medical School，前身为新泽西医学和牙科大学）的医学博士学位。
Thomas J. Errico,has been a board-certified orthopedic surgeon since 1986 and currently serves as a pediatric orthopedic spine surgeon at Nicklaus Children's Hospital. Dr. Errico also currently serves as the Associate Director of Research at Nicklaus Children's Hospital. He also is an associate Professor of Orthopedic Surgery at the University of Miami School of Medicine. He previously served as the chief, Division of Spine Surgery in Orthopedics, at NYU Langone Health from 1997 until 2018. He currently serves on the board of Setting Scoliosis Straight, a nonprofit organization focused on advancing medical techniques in the treatment of spinal deformities and was an adjunct professor of the Department of Orthopedic Surgery at NYU Grossman School of Medicine. In addition, Dr. Errico is a member of the International Society for the Advancement of Spine Surgery and served as its president from 2010 to 2011. He is also an original member of the North American Spine Society and served as its president from 2003 to 2004. Dr. Errico has founded multiple companies in the healthcare industry, including Spinecore, Inc. in 2001, where he served as a director until it was sold to Stryker, Inc. in 2004. Dr. Errico was also a founding member of K2M Group Holdings, Inc. in January 2004. Dr. Errico holds a B.S. in zoology from Rutgers University and an M.D. from Rutgers Medical School, formerly the University of Medicine and Dentistry of New Jersey.- ThomasJ.Errico自2005年9月以来一直担任我们的董事会成员，当时他与JosephP.Errico和PeterS.Staats共同创立了该公司。Errico博士从1986年开始一直担任董事会认证的整形外科医生，目前担任NYU Langone Health整形外科脊柱外科的部门主管，他从1997年开始担任该职位。他目前也是纽约大学医学院（NYU School of Medicine）骨科和神经外科教授。此外，Errico博士是国际脊柱外科进步协会（International Society for Advancement of Spine Surgery）的成员，并从2010年到2011年担任其总裁。他也是北美脊柱学会（North American Spine Society）的原始成员，并从2003年到2004年担任其总裁。Errico博士在梦百合行业创立了多家公司，包括SpineCore，Inc.，2002年，他在该公司担任董事，直到2004年该公司被出售给Stryker，Inc.。Errico博士还于2004年1月成为K2mGroupHoldings，Inc.的创始成员。Errico博士拥有罗格斯大学（Rutgers University）动物学学士学位和罗格斯医学院（Rutgers Medical School，前身为新泽西医学和牙科大学）的医学博士学位。
- Thomas J. Errico,has been a board-certified orthopedic surgeon since 1986 and currently serves as a pediatric orthopedic spine surgeon at Nicklaus Children's Hospital. Dr. Errico also currently serves as the Associate Director of Research at Nicklaus Children's Hospital. He also is an associate Professor of Orthopedic Surgery at the University of Miami School of Medicine. He previously served as the chief, Division of Spine Surgery in Orthopedics, at NYU Langone Health from 1997 until 2018. He currently serves on the board of Setting Scoliosis Straight, a nonprofit organization focused on advancing medical techniques in the treatment of spinal deformities and was an adjunct professor of the Department of Orthopedic Surgery at NYU Grossman School of Medicine. In addition, Dr. Errico is a member of the International Society for the Advancement of Spine Surgery and served as its president from 2010 to 2011. He is also an original member of the North American Spine Society and served as its president from 2003 to 2004. Dr. Errico has founded multiple companies in the healthcare industry, including Spinecore, Inc. in 2001, where he served as a director until it was sold to Stryker, Inc. in 2004. Dr. Errico was also a founding member of K2M Group Holdings, Inc. in January 2004. Dr. Errico holds a B.S. in zoology from Rutgers University and an M.D. from Rutgers Medical School, formerly the University of Medicine and Dentistry of New Jersey.
- Daniel S. Goldberger
DanielS.Goldberger自2018年4月以来一直担任Koru的董事。自2019年10月以来，Goldberger先生一直担任Electrocore Inc（一家将迷走神经刺激疗法商业化的上市公司）的首席执行官。从2017年10月至2019年1月，Goldberger先生担任Milestone Medical，Inc.的首席执行官。在此之前，他曾于2013年8月至2017年1月担任Xtant MedicalHoldings，Inc.首席执行官。他还从2007年4月到2013年2月担任Sound Surgical Technologies LLC首席执行官。Goldberger先生曾任职于Xtant MedicalHoldings，Inc.公司、Sound Surgical公司、Xcorporeal公司和Glucon公司的董事会。他目前担任投资基金Meridian Capital和Wellfleet Capital的顾问。Goldberger先生在M.I.T.获得机械工程学士学位，在斯坦福大学（Stanford University）获得机械工程硕士学位，并在斯坦福董事学院（Stanford Directors College）就读。
Daniel S. Goldberger,served as a director of Koru Medical Systems, a manufacturer of infusion pump systems, from April 2017 until May 2022 and he served as its executive chairman from August 2017 until September 2019. From January 2018 to September 2019, Mr. Goldberger served as the chief executive officer of Synergy Disc Replacement Inc., a private company commercializing a proprietary total disc implant for cervical spine therapy. From July 2017 to September 2017, Mr. Goldberger served as chief executive officer of Milestone Medical, Inc. Prior to this he served as the chief executive officer of Xtant Medical Holdings, Inc. from August 2013 to January 2017. He also served on the board and as the chief executive officer of Sound Surgical Technologies LLC from April 2007 to February 2013. Mr. Goldberger has also served on the boards of Xtant Medical Holdings, Inc., Sound Surgical, Xcorporeal. Theragen, Inc., and Glucon. Mr. Goldberger earned a B.S. in mechanical engineering from The Massachusetts Institute of Technology, and a M.S. in mechanical engineering from Stanford University.- DanielS.Goldberger自2018年4月以来一直担任Koru的董事。自2019年10月以来，Goldberger先生一直担任Electrocore Inc（一家将迷走神经刺激疗法商业化的上市公司）的首席执行官。从2017年10月至2019年1月，Goldberger先生担任Milestone Medical，Inc.的首席执行官。在此之前，他曾于2013年8月至2017年1月担任Xtant MedicalHoldings，Inc.首席执行官。他还从2007年4月到2013年2月担任Sound Surgical Technologies LLC首席执行官。Goldberger先生曾任职于Xtant MedicalHoldings，Inc.公司、Sound Surgical公司、Xcorporeal公司和Glucon公司的董事会。他目前担任投资基金Meridian Capital和Wellfleet Capital的顾问。Goldberger先生在M.I.T.获得机械工程学士学位，在斯坦福大学（Stanford University）获得机械工程硕士学位，并在斯坦福董事学院（Stanford Directors College）就读。
- Daniel S. Goldberger,served as a director of Koru Medical Systems, a manufacturer of infusion pump systems, from April 2017 until May 2022 and he served as its executive chairman from August 2017 until September 2019. From January 2018 to September 2019, Mr. Goldberger served as the chief executive officer of Synergy Disc Replacement Inc., a private company commercializing a proprietary total disc implant for cervical spine therapy. From July 2017 to September 2017, Mr. Goldberger served as chief executive officer of Milestone Medical, Inc. Prior to this he served as the chief executive officer of Xtant Medical Holdings, Inc. from August 2013 to January 2017. He also served on the board and as the chief executive officer of Sound Surgical Technologies LLC from April 2007 to February 2013. Mr. Goldberger has also served on the boards of Xtant Medical Holdings, Inc., Sound Surgical, Xcorporeal. Theragen, Inc., and Glucon. Mr. Goldberger earned a B.S. in mechanical engineering from The Massachusetts Institute of Technology, and a M.S. in mechanical engineering from Stanford University.
- Joshua S. Lev
Joshua S. Lev，自2022年1月起担任公司首席战略官，此前自2020年2月起担任业务发展、战略和财务规划副总裁。在加入公司之前，Lev先生作为投资银行家和专注于新兴成长型公司的投资者，在金融服务行业拥有超过15年的经验。2011年至2020年2月，Lev先生担任Wellfleet Partners，Inc.业务发展总监，专注于融资、并购、战略交易和机构客户关系。从2014年3月到2020年2月，他还是Aracle Capital，LLC的联合创始人，这是一家专注于早期和新兴成长型公司的投资公司。列夫先生获得了北卡罗来纳大学凯南-弗拉格勒商学院的工商管理硕士学位和叶史瓦大学SY Syms商学院的商业与管理学士学位。
Joshua S. Lev,has served as the Chief Strategy Officer of the Company since January 2022, previously having served as Vice President of Business Development, Strategy and Financial Planning since February 2020. Prior to joining the Company, Mr. Lev had over 15 years of experience in the financial services industry as an investment banker and investor focusing on emerging growth companies. From 2011 to February 2020, Mr. Lev served as Director of Business Development at Wellfleet Partners, Inc. focusing on capital raising, M&A, strategic transactions and institutional client relations. From March 2014 through February 2020, he was also a co-founder of Aracle Capital, LLC, an investment firm with a focus on early-stage and emerging-growth companies. Mr. Lev received an M.B.A. from the University of North Carolina's Kenan-Flagler Business School and a B.S. in Business & Management from the Sy Syms School of Business at Yeshiva University.- Joshua S. Lev，自2022年1月起担任公司首席战略官，此前自2020年2月起担任业务发展、战略和财务规划副总裁。在加入公司之前，Lev先生作为投资银行家和专注于新兴成长型公司的投资者，在金融服务行业拥有超过15年的经验。2011年至2020年2月，Lev先生担任Wellfleet Partners，Inc.业务发展总监，专注于融资、并购、战略交易和机构客户关系。从2014年3月到2020年2月，他还是Aracle Capital，LLC的联合创始人，这是一家专注于早期和新兴成长型公司的投资公司。列夫先生获得了北卡罗来纳大学凯南-弗拉格勒商学院的工商管理硕士学位和叶史瓦大学SY Syms商学院的商业与管理学士学位。
- Joshua S. Lev,has served as the Chief Strategy Officer of the Company since January 2022, previously having served as Vice President of Business Development, Strategy and Financial Planning since February 2020. Prior to joining the Company, Mr. Lev had over 15 years of experience in the financial services industry as an investment banker and investor focusing on emerging growth companies. From 2011 to February 2020, Mr. Lev served as Director of Business Development at Wellfleet Partners, Inc. focusing on capital raising, M&A, strategic transactions and institutional client relations. From March 2014 through February 2020, he was also a co-founder of Aracle Capital, LLC, an investment firm with a focus on early-stage and emerging-growth companies. Mr. Lev received an M.B.A. from the University of North Carolina's Kenan-Flagler Business School and a B.S. in Business & Management from the Sy Syms School of Business at Yeshiva University.